OL Cariprazine 3070-301-001
Protocol: STUDY00004941
Full Title
A 26-week, Multicenter, Open-label, Fleible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia or Bipolar I Disorder
This is a 26-week open-label study to evaluate the safety and effectiveness of the study drug in the treatment of pediatric participants with schizophrenia or bipolar I disorder.
Compensation: No
Males and females ages 13 to 18 with schizophrenia or 10 to 18 years of age with bipolar I disorder may be eligible for the study.
Age Group: Adults
Principal Investigator: STEVEN DUBOVSKY
+1 716-898-4038
Want to Learn More?

Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email ctsiresearch@buffalo.edu and someone will assist you.

Your information will be shared only with the research study team for recruitment purposes and designated CTSI personnel for project quality assurance and will remain confidential. Your information will be stored indefinitely. Should you no longer want this information to be provided in the aforementioned ways, please contact ctsiresearch@buffalo.edu.